Brand Names for Systemic Therapy in Moderate-to-Severe Plaque Psoriasis
There is no single "gold standard" brand name for moderate-to-severe plaque psoriasis, as the concept of a universal gold standard does not exist for this heterogeneous disease 1, 2. However, based on the most recent guidelines and expert consensus, the most commonly referenced systemic therapies with their brand names are:
Primary Systemic Treatment Options
The 2025 French guidelines recommend methotrexate, Humira (adalimumab), or Stelara (ustekinumab) as first-line systemic treatments for patients with psoriasis without symptomatic comorbidities 3.
TNF-α Inhibitors (Most Established)
- Remicade (infliximab) - Indicated for very severe plaque psoriasis (PASI ≥20, DLQI ≥18) when other systemic therapies have failed 1
- Humira (adalimumab) - FDA-approved for moderate-to-severe plaque psoriasis with Grade A recommendation 4
- Enbrel (etanercept) - Licensed for severe plaque psoriasis (PASI ≥10, DLQI >10) 1
IL-12/IL-23 Inhibitor
- Stelara (ustekinumab) - Grade A recommendation for moderate-to-severe plaque psoriasis 4
Understanding "Gold Standard" in Context
The term "gold standard" in psoriasis is context-dependent and varies by patient subgroup, disease location/extent, and psoriasis subtype 2. Among systemic agents, methotrexate was most frequently nominated by experts (17 out of 30) as the gold standard, though this reflects its widespread use and acceptance rather than superior efficacy 2.
Key Considerations:
- Efficacy hierarchy: Recent meta-analyses show that Remicade (infliximab), along with bimekizumab, ixekizumab, and risankizumab, demonstrate the highest clinical effectiveness 5
- Methotrexate remains recommended as first-line therapy but is less effective than Humira (adalimumab) and Remicade (infliximab) for cutaneous psoriasis 6
- No single treatment serves as the universal gold standard across all patient populations and disease presentations 2
Clinical Decision Algorithm
When selecting a brand-name systemic therapy:
- For patients without comorbidities: Start with methotrexate, Humira, or Stelara 3
- For maximum efficacy: Consider Remicade (though requires IV administration) 5
- For psoriatic arthritis: TNF-α inhibitors (Remicade, Humira, Enbrel) are preferred 1
- For patients requiring subcutaneous administration: Humira, Stelara, or Enbrel 1
Important Caveats:
- All listed biologics require prior failure, contraindication, or intolerance to conventional systemic therapies (ciclosporin, methotrexate, PUVA) 1
- Treatment selection should account for administration route preferences, dosing frequency, comorbidities (especially psoriatic arthritis), and specific psoriasis characteristics
- Remicade carries higher immunogenicity risk and requires concomitant methotrexate consideration to reduce antibody formation 4